First AD

Second AD

Jae Park, MD, is chief of Cellular Therapy Service at Memorial Sloan Kettering Cancer Center in New York, New York.

Jae Park, MD, presents long-term follow-up data from the FELIX study showing sustained remission in a subset of adult patients with relapsed/refractory B-ALL treated with obecabtagene autoleucel (obe-cel), with predictors of long-term benefit and no new safety concerns identified.

Can CAR T-cell therapy be a definitive treatment for adult r/r B-ALL without transplant? Long-term findings and predictors of sustained remission for obecabtagene autoleucel

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Jae Park, MD, presents long-term follow-up data from the FELIX study showing sustained remission in a subset of adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with obecabtagene autoleucel (obe-cel), with predictors of long-term benefit and no new safety concerns identified.

Can CAR T-Cell Therapy Be a Definitive Treatment for Adult R/R B-ALL Without Transplant? Long-Term Findings and Predictors of Sustained Remission for Obecabtagene Autoleucel